title: Efficacy and tolerability of moclobemide in comparison with placebo, tricyclic antidepressants, and selective serotonin reuptake inhibitors in elderly depressed patients: a clinical overview.
abstract: OBJECTIVE
  To review the efficacy and safety of moclobemide in comparison with TCAs (for our purposes, "TCAs" will represent tricyclic and tetracyclic antidepressants, including maprotilin and mianserin) and selective serotonin reuptake inhibitors (SSRIs) in elderly depressed patients.
  
  
  METHODS
  The efficacy data reviewed were obtained from the following sources: 1) results of published studies in the elderly; 2) data on patients aged > or = 60 years extracted from all available controlled trials in adults (> or = 18 years) in which moclobemide was compared with TCAs or SSRIs; and 3) the adverse events were extracted for patients aged > or = 60 years from the safety data base of all available comparative short-term studies with moclobemide versus TCAs, SSRIs, or placebo and of long-term studies with moclobemide.
  
  
  RESULTS
  The data show that moclobemide is an effective antidepressant in depressed patients aged > or = 60 years. The response rate to moclobemide was 50% to 55% in this population. Moclobemide was more effective than placebo and was of similar efficacy to the TCAs and the more recently introduced SSRIs. The tolerability of moclobemide was rated as "very good" or "good" in almost 90% of these patients, which was better than the tolerability of TCAs and similar to that of SSRIs. Patients without any adverse events were more frequently found in the moclobemide group than in those treated with TCAs (P < 0.01) or SSRIs (P < 0.01). Adverse events of the anticholinergic type were more frequent with TCAs than with moclobemide (P < 0.001), and nausea was found 3 times more frequently with SSRIs than with moclobemide (P < 0.01).
  
  
  CONCLUSIONS
  Moclobemide is an effective and well-tolerated antidepressant for the treatment of elderly depressed patients.
authors.affiliation: F Hoffmann-La Roche Ltd, Therapeutics Research CNS, Basel, Switzerland.
authors.forename: R
authors.initials: R
authors.lastname: Amrein
authors.forename: M
authors.initials: M
authors.lastname: Stabl
authors.forename: S
authors.initials: S
authors.lastname: Henauer
authors.forename: E
authors.initials: E
authors.lastname: Affolter
authors.forename: I
authors.initials: I
authors.lastname: Jonkanski
mesh_terms: D000368:Aged; D000928:Antidepressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000929:Antidepressive Agents, Tricyclic / Q000009:adverse effects / Q000627:therapeutic use; D001549:Benzamides / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D003071:Cognition / Q000187:drug effects; D016001:Confidence Intervals; D003863:Depression / Q000188:drug therapy*; D004347:Drug Interactions; D005852:Geriatric Psychiatry / Q000379:methods*; D006801:Humans; D008875:Middle Aged; D020912:Moclobemide; D008996:Monoamine Oxidase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D010919:Placebos; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000928:Antidepressive Agents; D000929:Antidepressive Agents, Tricyclic; D001549:Benzamides; D020912:Moclobemide; D008996:Monoamine Oxidase Inhibitors; D010919:Placebos; D017367:Selective Serotonin Reuptake Inhibitors